Comparison of autologous platelet rich fibrin and transplantation of autologous noncultured epidermal cell suspension in the treatment of chronic non healing ulcer
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: L89- Pressure ulcer
- Registration Number
- CTRI/2019/02/017788
- Lead Sponsor
- Department of Dermatology and Venereology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
chronic non healing ulcer of more than 6 weeks due to leprosy and diabetes and venous ulcer
Exclusion Criteria
age below 18 years
size more than 5x5 cm
pregnant and lactating woman
underlying osteomyelitis
patients in sepsis
malignancy
bleeding disorder
platelet below 1 lakh
patients on anticoagulant medication
uncontrolled diabetes mellitus
malignant ulcer
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the reduction in ulcer size over 5 monthsTimepoint: Follow up at every 2 weeks for first 2 months then monthly till 5 months
- Secondary Outcome Measures
Name Time Method To evaluate time to ulcer healing and improvement in discomfort and quality of lifeTimepoint: Follow up at every 2 weeks for first 2 months then monthly till 5 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie autologous platelet rich fibrin in chronic pressure ulcer healing?
How does autologous noncultured epidermal cell transplantation compare to standard wound care for L89 ulcers?
Which biomarkers correlate with successful autologous cell therapy outcomes in non healing ulcers?
What are the potential adverse events associated with platelet rich fibrin and epidermal cell suspension treatments?
Are there combination therapies involving platelet derived growth factors and epidermal cell grafts for chronic ulcer management?